SecBot SecBot

BSEM

BioStem Technologies, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. FL· CIK 0001658678 Biotech & Drug Discovery
$1.54 −0.03 (−1.91%)
Oct 26 4:00 PM ET · prev $1.57
Market cap
$29.3M
Nano cap
Median target
$7.00
+355% · range $7.00–7.00
Next earnings
Nov 17
in 21 days · EPS est. −$0.43
1 year
−65.8%
from $4.50 · Oct 28
30 days
−62.0%
from $4.05
52-week range
$1.54–8.20
−81% from high · low Oct 19
Avg volume 20D
137.9K
Oct 19 spike 403.7K
Short interest
333.8K
≈1.8% of shares · +239.1%
Days to cover
3.0
at average volume
Insider net
$0
no open-market trades · 12 mo
Filing reports
8
analyzed by SecBot
SecBot read BEARISH 9 reports · 90 days
Balance 6 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 9/9 ·Next Earnings date, Nov 17, 2026
Strongest BEARISH BioStem Technologies' S-1 registration (File No. 333-299282) became effective on October 9, 2026, enabling…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.460 → −$0.430 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersBUILDING

    Short interest +239.1% to 333.8K shares. 3.0 days to cover, ≈1.8% of shares.

  • TrendDOWNTREND

    52% below its 50-day average. New closing low $1.54 on Oct 26.

The Street

last action Nov 2022
12-month targets · 1 analysts

Price is below the lowest target. Median implies +355%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Nov 7, 2022Zacks Investment Research
INITIATE
INITIATEBuy
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 13, 2026 SEC
BioStem Technologies' S-1 registration (File No. 333-299282) became effective on October 9, 2026, enabling the company…
EFFECT — Impact 6/10
Oct 7, 2026 Insider
Matuszewski Jason acquired via exercise 250,000 shares
Chief Executive Officer @ $2.00 ($500.0K)
Oct 7, 2026 Insider
SMITH-VAN VURST ANDREW acquired via exercise 250,000 shares
Chief Operating Officer @ $2.00 ($500.0K)
Oct 2, 2026 SEC
BioStem Technologies filed an S-1 registration statement for the resale of up to 2,224,270 shares by selling…
S-1 — Impact 7/10
Oct 1, 2026 Other
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
Sep 30, 2026 SEC
BioStem Technologies raised approximately $3.0 million in a private placement priced at-the-market under Nasdaq rules…
8-K — Impact 6/10
Sep 21, 2026 Press
BioStem Technologies has joined the Terminal1 platform for shareholder intelligence, investor communications, and…
Impact 2/10
Sep 18, 2026 Press
BioStem Technologies announced a $40 million Committed Equity Facility (CEF) with Roth Principal Investments, allowing…
Impact 6/10

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 7, 2026
Matuszewski Jason
Chief Executive Officer
EXERCISE$500.0K
Oct 7, 2026
SMITH-VAN VURST ANDREW
Chief Operating Officer
EXERCISE$500.0K
Sep 17, 2026
Matuszewski Jason
Chief Executive Officer
EXERCISE16,650 sh
Sep 17, 2026
SMITH-VAN VURST ANDREW
Chief Operating Officer
EXERCISE9,574 sh
Sep 15, 2026
Matuszewski Jason
Chief Executive Officer
EXERCISE8,469 sh
Sep 15, 2026
WARRINGTON KENNETH HOWARD JR
Director
EXERCISE1,694 sh
Sep 15, 2026
FORTUNATO MICHAEL A
Chief Accounting Officer
EXERCISE4,234 sh
Sep 15, 2026
SMITH-VAN VURST ANDREW
Chief Operating Officer
EXERCISE7,622 sh

Earnings setup

Estimates
Nov 17
reports in 21 days
−$0.43
EPS estimate, this quarter
+7%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.43-$0.43–-$0.43+6.5%$7.2M
Next Q-$0.45-$0.45–-$0.45+2.2%$7.5M
Current FY-$1.90-$1.90–-$1.90+2.6%$28.7M
Next FY-$1.04-$1.04–-$1.04-235.5%$53.9M

Short side

FINRA· Oct 15, 2026
333,843
shares short
+239.1%
vs prior settlement
3.0
days to cover
≈1.8%
of shares outstanding
Trading halts
Aug 13, 2026Volatility PauseResumed
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 17, 2026
Earnings date
BSEM Q3 2026 Earnings Scheduled — 2026-11-17
Recent
Oct 1, 2026
Press release
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
Sep 21, 2026
Announcement
Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform
West Palm Beach, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Terminal1, the operating system built for public companies, announced today that BioStem…
Sep 18, 2026
Contract
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
Sep 4, 2026
Contract
BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
BioStem Technologies Expands Contracts with Two of the Largest Group Purchasing Organizations in the United States
Sep 3, 2026
Press release
BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Washington

Corporate Lobbying

7 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

SecBot reports

8 filings · 2 press releases · 0 bullish · 6 bearish · 2 neutral
All BSEM filing & press-release reports (10)